-
admin
Posts
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public...
Laughland Teeth Whitening Kit: Ingredients, Disclosures, and What Consumers Are Researching in 2026
A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product details, refund policies, and what consumers commonly research before purchasing...
Doorzo Ends 2025 with Its Strongest Year, Reaching a Decade Total of ¥80 Billion and Reinforcing Its Vision as “Your Gateway to Japan”
TOKYO, Feb. 7, 2026 /PRNewswire/ — SIG Service INC. (Headquarters: Chiyoda-ku, Tokyo), the operator of Doorzo, closed 2025 with record-breaking results, driven by its unwavering...
AWE Asia 2026 Concludes in Singapore, Signaling a More Grounded Phase for XR and AI
SINGAPORE, Feb. 7, 2026 /PRNewswire/ — AWE Asia 2026 concluded this week at Singapore Expo, convening the global extended reality (XR) and artificial intelligence (AI)...
LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE
Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion Therapies Data Presented at International Stroke Conference Data Show That LT3001 Delivers...
Frost & Sullivan: Human-Machine Integration and Manned-Unmanned Teaming to Reshape Global Military Operations Through 2027
Converging AI, autonomy, and secure communications push MUM-T from experimentation to scalable deployment LONDON, Feb. 7, 2026 /PRNewswire/ — According to a new Frost &...
CHANDO Presents Decade-Long Skin Brightening Research at IMCAS
Research Introduces 577 Epigenetic Mechanism for Asian Skin SHANGHAI, Feb. 7, 2026 /PRNewswire/ — The IMCAS World Congress 2026, an internationally recognized forum for aesthetic medicine...
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung disease Topline...
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline...
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo...
